as of 11-18-2026 10:27am EST
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 992.8M | IPO Year: | 2020 |
| Target Price: | $15.97 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $6.06 - $12.41 | Next Earning Date: | 11-10-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -39.4% | Revenue Growth (next year): | 14.22% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Director
Avg Cost/Share
$8.69
Shares
863,060
Total Value
$7,499,991.40
Owned After
11,246,516
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | IMTX | Director | Aug 26, 2026 | Buy | $8.69 | 863,060 | $7,499,991.40 | 11,246,516 |
See how IMTX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.